LEGN
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Legend Biotech Corporation
- Nom
- Legend Biotech Corporation
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $3.4B
- Employés
- 3,200
- PDG
- Alan S. Bash
- Site web
- https://www.legendbiotech.com
- Marché
- ALLOATRAAUTLCLLSCRBUDTIL
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 27 370 titres (~258 920,20 $ US)
- Insiders
- Sanders Corazon (Corsee) D.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$308,550
Avg sell (VWAP, 90d window) $9.41 vs last close $18.72 (+99.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-29
- Liquidity
- Liquid $44,808,799/day · 20d vol
- Last synced
-
2026-10-06 21:10:35
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-29 | Sanders Corazon (Corsee) D. | Sell · S | 27,370 | $9.46 | $258,920 | Form 4 |
| 2026-09-21 | Santos Carlos E | Sell · S | 5,430 | $9.14 | $49,630 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
LEGN presents a high-risk profile combining chronic negative profitability, persistent cash burn, and a weak liquidity cushion (score 65) with deteriorating fundamentals trend (score 35).
The first sentence of the analysis written for LEGN on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 1.96 · operating margin -13% — readings disagree
Suggested stop 17.51, nearest stored support minus 0.5 ATR(6.5% under the last close). Reward/risk to the next stored resistance is 2.36. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 60.3% | 62.6% | 49.4% | 44.1% | 100.0% | |
| Ebit Margin | -25.4% | -21.8% | -174.8% | -371.7% | -590.3% | |
| Ebitda Margin | -22.6% | -18.0% | -167.6% | -356.0% | -570.1% | |
| Operating Profit Margin | -13.3% | -48.3% | -154.1% | -389.4% | -570.0% | |
| Pretax Profit Margin | -27.5% | -25.2% | -182.4% | -380.9% | -591.6% | |
| Continuous Operations Profit Margin | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | |
| Net Profit Margin | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | |
| Bottom Line Profit Margin | -28.8% | -28.2% | -181.8% | -381.5% | -586.4% | |
| Current Ratio | 1.960 | 4.624 | 6.921 | 3.691 | 4.144 | |
| Quick Ratio | 1.909 | 4.538 | 6.831 | 3.656 | 4.136 | |
| Solvency Ratio | -0.366 | -0.244 | -0.834 | -0.729 | -1.102 | |
| Cash Ratio | 1.417 | 1.033 | 5.904 | 2.640 | 3.006 | |
| Price To Earnings Ratio | -13.587 | -33.546 | -20.466 | -17.765 | -17.011 | |
| Price To Earnings Growth Ratio | -0.209 | 0.501 | -4.424 | -6.954 | -2.572 | |
| Forward Price To Earnings Growth Ratio | -0.209 | 0.501 | -4.424 | -6.954 | -2.572 | |
| Price To Earnings Diluted Ratio | -13.587 | -33.546 | -20.466 | -17.765 | -17.011 | |
| Price To Earnings Diluted Growth Ratio | -0.209 | 0.501 | -4.424 | -6.954 | -2.572 | |
| Price To Book Ratio | 3.999 | 5.718 | 8.467 | 10.667 | 8.571 | |
| Price To Sales Ratio | 3.895 | 9.486 | 37.156 | 67.855 | 95.387 | |
| Price To Free Cash Flow Ratio | -23.846 | -37.625 | -25.469 | -35.514 | -26.921 | |
| Price To Operating Cash Flow Ratio | -39.886 | -41.310 | -26.940 | -39.444 | -33.079 | |
| Debt To Assets Ratio | 0.239 | 0.210 | 0.178 | 0.214 | 0.110 | |
| Debt To Equity Ratio | 0.413 | 0.337 | 0.263 | 0.382 | 0.161 | |
| Debt To Capital Ratio | 0.292 | 0.252 | 0.208 | 0.277 | 0.138 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.224 | 0.184 | 0.260 | 0.136 | |
| Financial Leverage Ratio | 1.730 | 1.605 | 1.477 | 1.788 | 1.462 | |
| Working Capital Turnover Ratio | 1.273 | 0.548 | 0.274 | 0.154 | 0.115 | |
| Operating Cash Flow Ratio | -0.158 | -0.519 | -1.817 | -0.676 | -0.866 | |
| Operating Cash Flow Sales Ratio | -0.098 | -0.230 | -1.379 | -1.720 | -2.884 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.673 | 1.098 | 1.058 | 1.111 | 1.229 | |
| Debt Service Coverage Ratio | -0.724 | -6.109 | -21.841 | -38.640 | -431.961 | |
| Interest Coverage Ratio | -6.379 | -14.029 | -20.165 | -42.203 | -435.874 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.315 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.243 | -0.411 | -1.197 | -0.707 | -1.614 | |
| Capital Expenditure Coverage Ratio | -1.487 | -10.211 | -17.308 | -9.036 | -4.371 | |
| Dividend Paid And Capex Coverage Ratio | -1.487 | -10.211 | -17.308 | -9.036 | -4.371 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -15.148 | -53.145 | -20.185 | -17.857 | -15.289 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 60.3% | ▼-2.3% | ▼-3.0% |
| Ebit Margin | -25.4% | ▼-3.6% | ▲211.4% |
| Ebitda Margin | -22.6% | ▼-4.5% | ▲204.3% |
| Operating Profit Margin | -13.3% | ▲35.1% | ▲221.8% |
| Pretax Profit Margin | -27.5% | ▼-2.3% | ▲214.1% |
| Continuous Operations Profit Margin | -28.8% | ▼-0.6% | ▲212.5% |
| Net Profit Margin | -28.8% | ▼-0.6% | ▲212.5% |
| Bottom Line Profit Margin | -28.8% | ▼-0.6% | ▲212.5% |
| Current Ratio | 1.960 | ▼-2.665 | ▼-2.308 |
| Quick Ratio | 1.909 | ▼-2.629 | ▼-2.305 |
| Solvency Ratio | -0.366 | ▼-0.122 | ▲0.289 |
| Cash Ratio | 1.417 | ▲0.384 | ▼-1.383 |
| Price To Earnings Ratio | -13.588 | ▲19.959 | ▲6.888 |
| Price To Earnings Growth Ratio | -0.209 | ▼-0.710 | ▲2.522 |
| Forward Price To Earnings Growth Ratio | -0.209 | ▼-0.710 | ▲2.522 |
| Price To Earnings Diluted Ratio | -13.588 | ▲19.959 | ▲6.888 |
| Price To Earnings Diluted Growth Ratio | -0.209 | ▼-0.710 | ▲2.522 |
| Price To Book Ratio | 3.999 | ▼-1.719 | ▼-3.486 |
| Price To Sales Ratio | 3.895 | ▼-5.591 | ▼-38.861 |
| Price To Free Cash Flow Ratio | -23.846 | ▲13.779 | ▲6.029 |
| Price To Operating Cash Flow Ratio | -39.886 | ▲1.424 | ▼-3.754 |
| Debt To Assets Ratio | 0.239 | ▲0.029 | ▲0.049 |
| Debt To Equity Ratio | 0.413 | ▲0.076 | ▲0.102 |
| Debt To Capital Ratio | 0.292 | ▲0.040 | ▲0.059 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.225 | ▼-0.161 |
| Financial Leverage Ratio | 1.730 | ▲0.125 | ▲0.118 |
| Working Capital Turnover Ratio | 1.273 | ▲0.724 | ▲0.800 |
| Operating Cash Flow Ratio | -0.158 | ▲0.361 | ▲0.649 |
| Operating Cash Flow Sales Ratio | -0.098 | ▲0.132 | ▲1.164 |
| Free Cash Flow Operating Cash Flow Ratio | 1.673 | ▲0.575 | ▲0.439 |
| Debt Service Coverage Ratio | -0.724 | ▲5.385 | ▲99.131 |
| Interest Coverage Ratio | -6.378 | ▲7.651 | ▲97.352 |
| Short Term Operating Cash Flow Coverage Ratio | -0.315 | ▼-0.315 | ▼-0.252 |
| Operating Cash Flow Coverage Ratio | -0.243 | ▲0.168 | ▲0.592 |
| Capital Expenditure Coverage Ratio | -1.487 | ▲8.725 | ▲6.996 |
| Dividend Paid And Capex Coverage Ratio | -1.487 | ▲8.725 | ▲6.996 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -15.148 | ▲37.997 | ▲9.177 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $4.01B | $5.95B | $10.59B | $7.94B | $6.57B | |
| Enterprise value | $3.52B | $6.01B | $9.65B | $7.44B | $6.00B | |
| EV / Sales | 3.42x | 9.59x | 33.83x | 63.57x | 87.16x | |
| EV / Op. cash flow | -35.03x | -41.75x | -24.53x | -36.95x | -30.23x | |
| EV / Free cash flow | -20.94x | -38.03x | -23.19x | -33.27x | -24.60x | |
| EV / EBITDA | -15.15x | -53.15x | -20.18x | -17.86x | -15.29x | |
| Net debt / EBITDA | 2.10x | -0.56x | 1.99x | 1.20x | 1.44x | |
| Current ratio | 1.96x | 4.62x | 6.92x | 3.69x | 4.14x | |
| Income quality | 0.34x | 0.91x | 0.76x | 0.45x | 0.49x | |
| Graham net-net | $2 | $3 | $5 | $3 | $4 | |
| Tax burden | 105.0% | 111.9% | 99.6% | 100.1% | 99.1% | |
| Interest burden | 108.2% | 115.8% | 104.4% | 102.5% | 100.2% | |
| Working capital | $610.7M | $1.01B | $1.28B | $801.3M | $720.6M | |
| Invested capital | $1.09B | $1.38B | $1.48B | $1.03B | $880.4M | |
| Return on assets | -17.1% | -10.6% | -28.0% | -33.5% | -36.1% | |
| Operating ROA | -8.0% | -17.2% | -27.6% | -37.2% | -42.6% | |
| Return on tangible assets | -17.9% | -11.8% | -28.1% | -35.4% | -36.6% | |
| Return on equity | -29.6% | -17.0% | -41.4% | -60.0% | -52.7% | |
| Return on invested capital | -9.6% | -21.7% | -26.8% | -43.9% | -43.6% | |
| Return on capital employed | -12.4% | -21.8% | -26.9% | -44.1% | -44.1% | |
| Earnings yield | -7.4% | -3.0% | -4.9% | -5.6% | -6.1% | |
| Free cash flow yield | -4.2% | -2.7% | -3.9% | -2.8% | -3.7% | |
| Capex / Op. cash flow | -67.3% | -9.8% | -5.8% | -11.1% | -22.9% | |
| Capex / Depreciation | 233.2% | 60.4% | 111.1% | 121.1% | 326.2% | |
| Capex / Sales | 6.6% | 2.2% | 8.0% | 19.0% | 66.0% | |
| SG&A / Sales | 33.2% | 45.3% | 70.5% | 148.8% | 217.2% | |
| R&D / Sales | 40.3% | 65.9% | 134.0% | 286.9% | 455.3% | |
| Stock comp / Sales | 0.0% | 11.0% | 16.7% | 29.3% | 29.3% | |
| Intangibles / Total assets | 4.3% | 10.4% | 0.2% | 5.2% | 1.5% | |
| Days sales outstanding | 89d | 73d | 201d | 139d | 310d | |
| Days payables outstanding | 73d | 58d | 51d | 177d | 0d | |
| Operating cycle | 117d | 110d | 250d | 197d | 310d | |
| Cash conversion cycle | 45d | 52d | 199d | 20d | 310d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-01 Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma.
- 2026-09-26 Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report) has been assigned a consensus rating of "Hold" from the fifteen brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and eight have given a buy recommendation to
- 2026-09-25 Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
- 2026-09-15 Legend Biotech taps Novartis veteran Zhang as CEO Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer therapy Carvykti.
- 2026-09-15 Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026.
- 2026-09-15 Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.
- 2026-09-10 Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland.
- 2026-09-01 Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m.
- 2026-08-12 Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More With all eyes locked on this morning''s CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.
- 2026-08-11 Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript